Publications by authors named "Andrea Sartore-Bianchi"

100Publications

Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities.

Cancer Treat Rev 2020 Dec 9;91:102112. Epub 2020 Oct 9.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano, Milano, Italy. Electronic address:

View Article and Find Full Text PDF
December 2020

Breaking Barriers in HER2+ Cancers.

Cancer Cell 2020 Sep 27;38(3):317-319. Epub 2020 Aug 27.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Milano, Italy.

View Article and Find Full Text PDF
September 2020

Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.

Expert Rev Anticancer Ther 2020 05 8;20(5):333-341. Epub 2020 Apr 8.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

View Article and Find Full Text PDF
May 2020

Liquid biopsy for rectal cancer: A systematic review.

Cancer Treat Rev 2019 Sep 31;79:101893. Epub 2019 Aug 31.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Università degli Studi di Milano, Department of Oncology and Hemato-Oncology, Milan, Italy. Electronic address:

View Article and Find Full Text PDF
September 2019

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer.

JAMA Oncol 2019 Aug 15. Epub 2019 Aug 15.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

View Article and Find Full Text PDF
August 2019

Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.

Cancer Treat Rev 2019 Feb 27;73:41-53. Epub 2018 Dec 27.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Università degli Studi di Milano, Dipartimento di Oncologia ed Emato-Oncologia, Milano, Italy. Electronic address:

View Article and Find Full Text PDF
February 2019

Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.

Clin Colorectal Cancer 2019 03 16;18(1):e117-e129. Epub 2018 Nov 16.

Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University Vienna, Vienna, Austria. Electronic address:

View Article and Find Full Text PDF
March 2019

Early-onset colorectal cancer in young individuals.

Mol Oncol 2019 02 22;13(2):109-131. Epub 2018 Dec 22.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano (La Statale), Milan, Italy.

View Article and Find Full Text PDF
February 2019

Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer.

JAMA Oncol 2018 Jan;4(1):19-20

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.

View Article and Find Full Text PDF
January 2018

Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.

Handb Exp Pharmacol 2018;249:145-159

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore, 3, 20162, Milan, Italy.

View Article and Find Full Text PDF
June 2019

Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.

Clin Colorectal Cancer 2017 09 25;16(3):e153-e163. Epub 2017 Jan 25.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milano, Italy.

View Article and Find Full Text PDF
September 2017

Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer: What Happens at Relapse?

JAMA Oncol 2017 04;3(4):481-482

Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy.

View Article and Find Full Text PDF
April 2017

Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR.

Cancer Treat Rev 2016 Dec 29;51:54-62. Epub 2016 Oct 29.

Department of Medical Oncology, Campus Bio-Medico University of Rome, 00128 Rome, Italy. Electronic address:

View Article and Find Full Text PDF
December 2016

Clonal evolution and - coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer.

ESMO Open 2016 4;1(4):e000079. Epub 2016 Aug 4.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milano, Italy.

View Article and Find Full Text PDF
August 2016

gene fusions as novel targets of cancer therapy across multiple tumour types.

ESMO Open 2016 18;1(2):e000023. Epub 2016 Mar 18.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.

View Article and Find Full Text PDF
March 2016

Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study.

Clin Colorectal Cancer 2016 09 19;15(3):213-21. Epub 2016 Feb 19.

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy.

View Article and Find Full Text PDF
September 2016

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.

J Natl Cancer Inst 2016 Jan 12;108(1). Epub 2015 Nov 12.

Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy (ASB, AA, EV, LP, EB, GM, SV, AV, SS); Nerviano Medical Sciences S.r.l Nerviano, Milan, Italy (EA, RB, AS, LR, PB, AL, RA, AG, AI); Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Torino, Italy (SM, AB); University of Torino, Department of Oncology, Candiolo, Torino, Italy (AB); FIRC Institute of Molecular Oncology (IFOM), Milano, Italy (SM); Ignyta, Inc., San Diego, CA (DL, ZH, JL); Clioss S.r.l. Nerviano, Milan, Italy (MM, CD); Università degli Studi di Milano, Milan, Italy (SS).

View Article and Find Full Text PDF
January 2016

Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function.

Int J Biol Markers 2015 Jul 22;30(3):e275-81. Epub 2015 Jul 22.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (Forlì-Cesena) - Italy.

View Article and Find Full Text PDF
July 2015

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

Cancer Discov 2014 Nov 7;4(11):1269-80. Epub 2014 Oct 7.

Department of Oncology, University of Torino, Candiolo, Torino, Italy. Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Torino, Italy. FIRC Institute of Molecular Oncology (IFOM), Milano, Italy.

View Article and Find Full Text PDF
November 2014

Acquired resistance to EGFR-targeted therapies in colorectal cancer.

Mol Oncol 2014 Sep 14;8(6):1084-94. Epub 2014 May 14.

Candiolo Cancer Institute - FPO, IRCCS, Str prov 142 Km 3.95, 10060 Candiolo, Torino, Italy; University of Torino, Department of Oncology, Strada Provinciale, 142 km 3.95, 10060 Candiolo, Torino, Italy. Electronic address:

View Article and Find Full Text PDF
September 2014

Regorafenib in metastatic colorectal cancer.

Expert Rev Anticancer Ther 2014 Mar;14(3):255-65

Department of Hematology and Oncology, Niguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, Italy.

View Article and Find Full Text PDF
March 2014

Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.

J Natl Cancer Inst 2014 Jan 22;106(1):djt322. Epub 2013 Nov 22.

Affiliations of authors: Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain (CM, AM-C, FJC, ME); Medical Oncology Service, Catalan Institute of Oncology, Health Sciences Research Institute of the Germans Trias i Pujol Foundation, Barcelona, Spain (AM-C, EM-B, AA); Department of Medical Oncology (CS, RS) and Clinical Informatics Unit (VN-P), Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain; Department of Pathology, Germans Trias i Pujol Foundation, Barcelona, Spain (EM); Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy (AS-B, AC, SS); Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain (EE, JT); Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Barcelona, Spain (ME); Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain (ME).

View Article and Find Full Text PDF
January 2014

New frontiers in therapeutic resistance in cancer.

Expert Rev Anticancer Ther 2012 Jul;12(7):877-9

Falck Division of Medical Oncology, Department of Oncology, Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore, 3 20162 Milano, Italy.

View Article and Find Full Text PDF
July 2012

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

J Natl Cancer Inst 2009 Oct 8;101(19):1308-24. Epub 2009 Sep 8.

The Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.

View Article and Find Full Text PDF
October 2009

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

J Clin Oncol 2008 Dec 10;26(35):5705-12. Epub 2008 Nov 10.

Laboratory of Molecular Genetics, The Oncogenomics Center, Institute for Cancer Research and Treatment, University of Torino, Medical School, Candiolo, Torino, Italy.

View Article and Find Full Text PDF
December 2008

EGFR FISH in colorectal cancer: what is the current reality?

Lancet Oncol 2008 May;9(5):402-3

Falck Division of Medical Oncology, Niguarda Ca' Granda Hospital, 20162 Milan, Italy.

View Article and Find Full Text PDF
May 2008

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

Clin Cancer Res 2007 Oct;13(19):5942-51

Institute of Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo University Hospital, 1-27100 Pavia [corrected] Italy.

View Article and Find Full Text PDF
October 2007